Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2004-01-13 Regulatory Filings
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
MorphoSys to Cross-License Technologies with Bayer
Regulatory Filings Classification · 100% confidence The document is a corporate news announcement dated January 13, 2004, detailing a cross-licensing agreement between MorphoSys AG and Bayer HealthCare regarding antibody technologies. This type of announcement, which details a significant business transaction (licensing, collaboration expansion), does not fit the specific definitions for financial reports (10-K, IR, ER), governance documents (CGR, DEF 14A), or shareholder actions (DIV, DVA). Since it is a general corporate news item about a strategic business development that doesn't fit the more specific categories like M&A (TAR) or Financing (CAP), the most appropriate general category is Regulatory Filings (RNS), which serves as the fallback for miscellaneous regulatory announcements not covered elsewhere. Given the content is a specific business deal announcement, RNS is the best fit among the available options.
2004-01-13 English
MorphoSys Forges Therapeutic Antibody Collaboration with Pfizer
Regulatory Filings Classification · 100% confidence The document is labeled as an 'Ad-hoc' announcement dated December 22, 2003. It details a specific business event: a collaboration agreement between MorphoSys and Pfizer regarding therapeutic antibody development. This type of announcement, which is a material, non-scheduled disclosure about a significant business development (like a major partnership or financing event), typically falls under general regulatory announcements or specific categories related to financing/transactions. Since it describes a strategic collaboration and potential future payments (milestones/royalties), it relates to corporate activity. It is not a formal financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). Given the nature of announcing a significant business deal that involves future financial considerations, it fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous, material, ad-hoc disclosure that doesn't fit the more specific financial or governance codes. It is too specific for RNS if a better fit existed, but among the options, RNS serves as the best catch-all for non-standard, material announcements not covered elsewhere.
2003-12-22 English
MorphoSys Presents Animal Data for Antibodies to Treat Alzheimer's Disease
Regulatory Filings Classification · 97% confidence The document is a 'News Details' announcement sent via DGAP (a common German regulatory news distribution service). It details scientific progress (animal data presentation at a conference) related to a collaboration between MorphoSys and Roche concerning Alzheimer's disease antibodies. This type of announcement, focusing on scientific milestones, corporate collaborations, and general business updates rather than specific financial results (ER/IR), management changes (MANG), or formal regulatory filings (10-K/AR), fits best under the general category for corporate news announcements that don't fit elsewhere. Since it is a corporate news announcement about research progress and collaboration milestones, and not a formal financial report, proxy statement, or insider trade, the most appropriate classification is 'Regulatory Filings' (RNS) as a general corporate announcement fallback, although 'LTR' (Legal Proceedings Report) or 'IP' (Investor Presentation) are less fitting. Given the context of a press release announcing scientific data presentation, RNS serves as the best general corporate news category available.
2003-12-03 English
MorphoSys Issued U.S. Patent for HuCAL EST Technology
Regulatory Filings Classification · 100% confidence The document is a short corporate news announcement dated November 27, 2003, detailing the issuance of a U.S. Patent for MorphoSys's HuCAL EST Technology. It is not a comprehensive financial report (like 10-K or IR), nor is it a transcript, management discussion, or proxy material. It is a specific announcement regarding intellectual property and corporate development. Since it is a general corporate news announcement that doesn't fit into the highly specific categories like DIRS, DIV, or CAP, the most appropriate fallback category is Regulatory Filings (RNS), which covers general regulatory announcements not covered elsewhere.
2003-11-27 English
Boehringer Ingelheim Exercises Option in Antibody Collaboration with MorphoSys
Regulatory Filings Classification · 100% confidence The document is a short corporate news announcement dated November 18, 2003, detailing a specific business event: Boehringer Ingelheim exercising an option in an antibody collaboration with MorphoSys. It describes the terms of the agreement (development, milestones, royalties) but does not contain comprehensive financial statements (like a 10-K or IR) or detailed management analysis (like MDA). It is a specific business development update. Since there is no specific category for 'Collaboration Announcement' or 'Business Development Update', and it is not a standard regulatory filing like a Director's Dealing (DIRS) or Major Shareholding (MRQ), it falls best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate announcement sent via DGAP, or potentially 'Capital/Financing Update' (CAP) if the exercise implied a significant financial commitment, but RNS is the most appropriate fallback for general news releases that don't fit the other specific types. Given the nature of the announcement (a specific corporate action/agreement update), RNS is the best fit as a general regulatory news release.
2003-11-18 English
MorphoSys AG english
Earnings Release Classification · 100% confidence The document explicitly states it reports 'financial results for its third quarter and nine months ended September 30, 2003.' It provides detailed financial figures (revenues, expenses, net loss, EPS) for this period. This content structure is characteristic of a periodic financial report covering a period shorter than a full year. The presence of a conference call announcement ('The Management of MorphoSys will hold a public conference call today at 10:00 CET to present the financial results of the third quarter 2003') suggests this is the primary release of the results, which aligns best with the 'Earnings Release' (ER) definition, although it contains more detail than a typical highlights-only release. However, since it covers a comprehensive quarterly period (nine months ended Sept 30), it also strongly resembles an 'Interim / Quarterly Report' (IR). Given the depth of financial data provided, IR is a better fit than the brief ER, unless the document is merely an announcement pointing to the full report. Since the text contains the actual results and not just a notice that results are available, it is classified as the report itself. IR is chosen over ER because it covers the nine-month period comprehensively. 9M 2003
2003-10-29 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.